Fate Therapeutics (FATE) Competitors $1.55 -0.12 (-7.19%) Closing price 06/11/2025 04:00 PM EasternExtended Trading$1.53 -0.02 (-1.29%) As of 09:26 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock FATE vs. ANAB, XNCR, AVXL, ABUS, SANA, TRVI, BCAX, AUTL, EOLS, and PHATShould you be buying Fate Therapeutics stock or one of its competitors? The main competitors of Fate Therapeutics include AnaptysBio (ANAB), Xencor (XNCR), Anavex Life Sciences (AVXL), Arbutus Biopharma (ABUS), Sana Biotechnology (SANA), Trevi Therapeutics (TRVI), Bicara Therapeutics (BCAX), Autolus Therapeutics (AUTL), Evolus (EOLS), and Phathom Pharmaceuticals (PHAT). These companies are all part of the "pharmaceutical products" industry. Fate Therapeutics vs. Its Competitors AnaptysBio Xencor Anavex Life Sciences Arbutus Biopharma Sana Biotechnology Trevi Therapeutics Bicara Therapeutics Autolus Therapeutics Evolus Phathom Pharmaceuticals Fate Therapeutics (NASDAQ:FATE) and AnaptysBio (NASDAQ:ANAB) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, risk, profitability, dividends, analyst recommendations, valuation, institutional ownership, community ranking and media sentiment. Is FATE or ANAB more profitable? AnaptysBio has a net margin of -289.75% compared to Fate Therapeutics' net margin of -1,325.43%. Fate Therapeutics' return on equity of -45.88% beat AnaptysBio's return on equity.Company Net Margins Return on Equity Return on Assets Fate Therapeutics-1,325.43% -45.88% -33.95% AnaptysBio -289.75%-287.94%-37.25% Does the MarketBeat Community favor FATE or ANAB? Fate Therapeutics received 101 more outperform votes than AnaptysBio when rated by MarketBeat users. Likewise, 67.18% of users gave Fate Therapeutics an outperform vote while only 66.55% of users gave AnaptysBio an outperform vote. CompanyUnderperformOutperformFate TherapeuticsOutperform Votes48167.18% Underperform Votes23532.82% AnaptysBioOutperform Votes38066.55% Underperform Votes19133.45% Which has stronger earnings & valuation, FATE or ANAB? Fate Therapeutics has higher earnings, but lower revenue than AnaptysBio. AnaptysBio is trading at a lower price-to-earnings ratio than Fate Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioFate Therapeutics$13.34M13.32-$160.93M-$1.49-1.04AnaptysBio$111.87M6.20-$163.62M-$4.85-4.87 Do analysts prefer FATE or ANAB? Fate Therapeutics currently has a consensus price target of $4.14, indicating a potential upside of 167.28%. AnaptysBio has a consensus price target of $42.38, indicating a potential upside of 79.56%. Given Fate Therapeutics' higher possible upside, research analysts plainly believe Fate Therapeutics is more favorable than AnaptysBio.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Fate Therapeutics 0 Sell rating(s) 7 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.22AnaptysBio 0 Sell rating(s) 3 Hold rating(s) 6 Buy rating(s) 1 Strong Buy rating(s) 2.80 Does the media favor FATE or ANAB? In the previous week, Fate Therapeutics had 1 more articles in the media than AnaptysBio. MarketBeat recorded 9 mentions for Fate Therapeutics and 8 mentions for AnaptysBio. Fate Therapeutics' average media sentiment score of 0.86 beat AnaptysBio's score of 0.73 indicating that Fate Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Fate Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive AnaptysBio 2 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has more volatility & risk, FATE or ANAB? Fate Therapeutics has a beta of 2.23, indicating that its stock price is 123% more volatile than the S&P 500. Comparatively, AnaptysBio has a beta of -0.26, indicating that its stock price is 126% less volatile than the S&P 500. Do institutionals & insiders have more ownership in FATE or ANAB? 97.5% of Fate Therapeutics shares are held by institutional investors. 5.5% of Fate Therapeutics shares are held by company insiders. Comparatively, 33.5% of AnaptysBio shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth. SummaryFate Therapeutics beats AnaptysBio on 13 of the 19 factors compared between the two stocks. Get Fate Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for FATE and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding FATE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart FATE vs. The Competition Export to ExcelMetricFate TherapeuticsBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$191.39M$3.09B$5.57B$8.63BDividend YieldN/A1.58%5.28%4.18%P/E Ratio-0.9433.3227.1420.06Price / Sales13.32469.84411.98157.10Price / CashN/A168.6838.2534.64Price / Book0.413.457.064.70Net Income-$160.93M-$72.35M$3.23B$247.88M7 Day Performance15.67%6.23%2.85%2.63%1 Month Performance44.86%16.53%9.06%6.36%1 Year Performance-58.89%-16.90%31.43%14.05% Fate Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)FATEFate Therapeutics4.146 of 5 stars$1.55-7.2%$4.14+167.3%-60.2%$191.39M$13.34M-0.94550Analyst RevisionGap UpANABAnaptysBio1.7815 of 5 stars$23.19-2.2%$42.38+82.7%-0.2%$681.32M$111.87M-3.81100XNCRXencor4.1934 of 5 stars$9.55-1.0%$29.50+208.9%-56.6%$679.68M$127.23M-2.98280Positive NewsAVXLAnavex Life Sciences3.9304 of 5 stars$7.93-4.1%$44.00+454.9%+121.6%$677MN/A-14.4240Positive NewsABUSArbutus Biopharma2.2499 of 5 stars$3.51+0.9%$5.50+56.7%+10.1%$672.26M$6.40M-8.1690Positive NewsSANASana Biotechnology2.4885 of 5 stars$2.83-0.4%$10.80+281.6%-60.8%$640.36MN/A-2.02380Positive NewsTRVITrevi Therapeutics3.5061 of 5 stars$6.41-9.2%$18.63+190.6%+140.4%$640.31MN/A-14.5720BCAXBicara Therapeutics2.3388 of 5 stars$11.48-0.2%$31.86+177.5%N/A$626.07MN/A0.0032Analyst RevisionAUTLAutolus Therapeutics2.6465 of 5 stars$2.35+0.4%$9.32+296.6%-48.0%$625.43M$9.01M-1.94330Positive NewsEOLSEvolus4.1084 of 5 stars$9.65-3.9%$23.75+146.1%-11.6%$622.19M$275.46M-10.60170Insider TradeHigh Trading VolumePHATPhathom Pharmaceuticals4.0871 of 5 stars$8.83-1.0%$17.50+98.2%-18.0%$616.46M$81.86M-1.55110Analyst ForecastOptions VolumeHigh Trading Volume Related Companies and Tools Related Companies AnaptysBio Alternatives Xencor Alternatives Anavex Life Sciences Alternatives Arbutus Biopharma Alternatives Sana Biotechnology Alternatives Trevi Therapeutics Alternatives Bicara Therapeutics Alternatives Autolus Therapeutics Alternatives Evolus Alternatives Phathom Pharmaceuticals Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:FATE) was last updated on 6/12/2025 by MarketBeat.com Staff From Our PartnersTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredNew Rule Hits in July — The Smart Money Already MovedA little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Stre...American Alternative | SponsoredGold is soaring. Here’s how to get paid from itGold just broke through $3,300… And while the headlines shout about price targets, something even more powe...Investors Alley | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | Sponsored2025 Market Crash50-Year Legend: Here's The Day Stocks Likely Crash Investing legend finds best cycle indicator during 50-ye...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Fate Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Fate Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy FATE Stock Free FATE Stock Alerts